All treatment comparisons

Treatment Comparison  ·  Reviewed by Dr. Ben Soffer, DO

Lexapro vs Wellbutrin

SSRI vs NDRI — two fundamentally different mechanisms for depression

TL;DR

  • Lexapro (escitalopram) and Wellbutrin (bupropion) work on completely different neurotransmitter systems — serotonin vs dopamine + norepinephrine.
  • Wellbutrin is the most-prescribed antidepressant that does NOT cause sexual dysfunction or weight gain — major reason patients ask to switch from SSRIs.
  • Wellbutrin tends to be activating; Lexapro tends to be calming. For depression-with-anxiety, Lexapro is usually preferred; for depression-with-fatigue-and-anhedonia, Wellbutrin is.
  • Wellbutrin lowers seizure threshold — contraindicated in patients with seizure disorders, eating disorders (bulimia/anorexia), or significant alcohol-withdrawal risk.
  • Both take 4-6 weeks for full response, though some Wellbutrin patients report energy/motivation improvement within 1-2 weeks.
  • Combining them is common ("California Rocket Fuel" minus the SNRI — Lexapro plus Wellbutrin) and often helps patients who partially respond to either alone.

Side by side

Lexapro

Escitalopram

SSRI (selective serotonin reuptake inhibitor)

What it treats

Major depression, Generalized anxiety disorder, Off-label: panic, social anxiety, OCD

Mechanism

Selectively blocks serotonin reuptake at the serotonin transporter. Pure S-enantiomer of citalopram with the cleanest SSRI side-effect profile.

Strengths

  • Cleanest side-effect profile in the SSRI class
  • Strong evidence in anxiety alongside depression
  • Once-daily dosing, simple titration
  • Minimal drug-drug interactions

Limitations

  • Sexual dysfunction in 30-50% of patients
  • Weight gain over months
  • Emotional blunting in some patients
  • Can be activating in early weeks before settling

Wellbutrin

Bupropion

NDRI (norepinephrine-dopamine reuptake inhibitor)

What it treats

Major depression, Seasonal affective disorder, Smoking cessation (as Zyban), Off-label: ADHD adjunct

Mechanism

Blocks reuptake of dopamine and norepinephrine — does NOT affect serotonin meaningfully. The only marketed mainstream antidepressant with this profile.

Strengths

  • No sexual dysfunction (major patient preference reason)
  • No weight gain — sometimes mild weight loss
  • Activating effect helps low-energy/anhedonia presentations
  • Smoking-cessation benefit in patients trying to quit

Limitations

  • Lowers seizure threshold (contraindicated in seizure / eating disorder / alcohol withdrawal)
  • Can worsen anxiety in some patients
  • Insomnia if dosed too late in day
  • Twice-daily IR dosing or once-daily XL formulation

Which one for your situation?

If:

Depression with anxiety as a major component

Verdict:

Lexapro — Wellbutrin can worsen anxiety in some patients

If:

Depression with anhedonia, low motivation, fatigue

Verdict:

Wellbutrin — its dopaminergic activation targets exactly these symptoms

If:

Patient wants to avoid sexual dysfunction or weight gain

Verdict:

Wellbutrin — this is the #1 reason patients request a switch from SSRIs

If:

History of seizures, eating disorder, or active alcohol withdrawal

Verdict:

Lexapro — Wellbutrin is contraindicated in these scenarios

If:

Trying to quit smoking

Verdict:

Wellbutrin — has FDA approval as Zyban for smoking cessation

If:

Partial response to one — augmenting

Verdict:

Combining Lexapro + Wellbutrin is a common clinical maneuver that often produces full response where either alone produced partial

Where ketamine fits

For patients who've tried both Lexapro and Wellbutrin (or the combination) without sufficient response, the technical criteria for treatment-resistant depression apply. Ketamine's NMDA/glutamate mechanism is entirely different from either serotonin or dopamine reuptake — a meaningful mechanism switch with the strongest evidence base in treatment-resistant cases.

Lexapro and Wellbutrin both take 4-6 weeks to produce full response. Sublingual ketamine produces measurable mood improvement within hours of the first session.

Check eligibility for ketamine therapy

5-minute screening · Reviewed by a board-certified physician · FL & NJ

Frequently asked

Will Wellbutrin make me lose weight?

For some patients, modestly — Wellbutrin is the only antidepressant typically associated with mild weight loss or weight neutrality (most others cause gain). Don't take it for weight loss as a primary purpose; the FDA-approved indication is depression, and the effect is mild (~2-4 lbs on average).

Will Wellbutrin help my sexual function come back?

If sexual dysfunction is from your current SSRI, switching to Wellbutrin typically restores function — bupropion does NOT cause the sexual side effects SSRIs are known for. This is the most common patient-requested reason for the switch.

Can I take both Lexapro and Wellbutrin?

Yes, combining them is a common and well-tolerated combination. The strategy: Lexapro handles serotonin-mediated depression and anxiety; Wellbutrin handles energy, motivation, and counteracts SSRI sexual dysfunction. Many patients on this combination do better than on either alone.

I tried both and neither worked well. What's next?

After two adequate antidepressant trials from different mechanism classes, the technical definition of treatment-resistant depression applies. Options include SNRIs (Effexor, Cymbalta), augmentation strategies (lithium, atypical antipsychotics), TMS, or ketamine. Ketamine specifically has the strongest evidence in the treatment-resistant subset and works on a completely different mechanism (NMDA/glutamate).

How long should I try each before switching?

6-8 weeks at a therapeutic dose is standard before declaring non-response. Wellbutrin patients sometimes report energy improvement within 1-2 weeks; that's a positive signal but the full response window is the same as SSRIs.

References

  1. Cipriani A et al. 2018, Lancet. Network meta-analysis ranking 21 antidepressants — escitalopram and bupropion both ranked in the top efficacy tier, with bupropion notably preferred for tolerability. PMID 29477251
  2. Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT in treatment-resistant depression — 64% response vs 28% placebo, including patients who had failed both SSRIs and NDRIs. PMID 23982301

Other treatment comparisons